Horizon Pharma Company Profile (NASDAQ:HZNP)

Analyst Ratings

Consensus Ratings for Horizon Pharma (NASDAQ:HZNP) (?)
Ratings Breakdown: 2 Hold Rating(s), 11 Buy Rating(s)
Consensus Rating:Buy (Score: 2.85)
Consensus Price Target: $30.73 (56.61% upside)

Analysts' Ratings History for Horizon Pharma (NASDAQ:HZNP)
Show:
DateFirmActionRatingPrice TargetActions
7/14/2016Brean CapitalReiterated RatingBuy$30.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/11/2016Morgan StanleyUpgradeUnderweight -> Equal Weight$24.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/6/2016Stifel NicolausReiterated RatingBuy$45.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/28/2016BMO Capital MarketsInitiated CoverageOutperform$29.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/6/2016Goldman Sachs Group Inc.Initiated CoverageBuy$24.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/1/2016Citigroup Inc.Initiated CoverageNeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/10/2016Piper Jaffray Cos.Reiterated RatingOverweight$44.00 -> $34.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/10/2016GuggenheimReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/10/2016MizuhoReiterated RatingBuy$25.00 -> $24.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/2/2016Cowen and CompanyReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/3/2016Jefferies GroupReiterated RatingBuy$31.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/11/2015WallachBeth CapitalUpgradeBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/22/2015JMP SecuritiesReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/7/2015Leerink SwannReiterated RatingPositive$37.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/9/2014Avondale PartnersInitiated CoverageOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/29/2014 forward)

Earnings

Earnings History for Horizon Pharma (NASDAQ:HZNP)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/8/2016        
5/9/2016Q116$0.30$0.34$197.73 million$204.70 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/29/2016Q415$0.62$0.63$240.92 million$244.50 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/6/2015Q315$0.40$0.70$185.70 million$292.70 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/7/2015Q215$0.32$0.39$156.41 million$172.80 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/8/2015Q115$0.21$0.21$104.20 million$113.10 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/27/2015Q414$0.23$0.27$95.50 million$103.80 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/6/2014Q314$0.17$0.24$73.17 million$75.10 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/7/2014Q214$0.10$0.21$58.35 million$66.10 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/9/2014Q114$0.01$0.16$42.69 million$51.90 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/13/2014Q413($0.08)($0.22)$32.20 million$43.10 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/8/2013Q3 13($0.25)($0.03)$18.31 million$31.50 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/9/2013Q213($0.32)($0.24)$16.09 million$17.64 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/10/2013Q113($0.35)($0.30)$9.47 million$9.20 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/13/2012Q312($0.68)($0.39)$4.12 million$7.20 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Horizon Pharma (NASDAQ:HZNP)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161$0.58$0.58$0.58
Q2 20161$0.49$0.49$0.49
Q3 20161$0.70$0.70$0.70
Q4 20161$0.85$0.85$0.85
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Horizon Pharma (NASDAQ:HZNP)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Horizon Pharma (NASDAQ:HZNP)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/15/2016Virinder NohriaDirectorSell25,000$17.69$442,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/26/2016Jeffrey W ShermanEVPSell4,100$20.00$82,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/10/2015Jeffrey W ShermanEVPSell4,456$20.00$89,120.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/21/2015Jeffrey W ShermanEVPSell7,750$31.78$246,295.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/15/2015Jeffrey W ShermanEVPSell26,887$35.55$955,832.85View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/13/2015Jeff HimawanDirectorSell554,564$22.44$12,444,416.16View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/10/2015Jeff HimawanDirectorSell1,614,827$21.85$35,283,969.95View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/19/2014Jeff HimawanDirectorSell3,450,000$12.05$41,572,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/19/2014Jeffrey W ShermanEVPSell24,999$12.05$301,237.95View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/19/2014Timothy P WalbertCEOSell150,000$12.05$1,807,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/13/2014Balaji VenkataramanMajor ShareholderSell6,086,957$11.54$70,243,483.78View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/13/2014Virinder NohriaDirectorSell1,739,130$11.54$20,069,560.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/30/2014Vaere Robert J DeCFOSell51,942$12.28$637,847.76View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/19/2014Timothy WalbertCEOSell31,742$12.94$410,741.48View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/19/2014Todd SmithEVPSell10,159$12.94$131,457.46View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/19/2014Vaere Robert DeCFOSell12,939$12.94$167,430.66View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/13/2013Jeffrey BirdDirectorBuy668,673$6.50$4,346,374.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/9/2013Timothy WalbertCEOSell12,124$6.79$82,321.96View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/9/2013Todd SmithEVPSell11,322$6.91$78,235.02View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/21/2013Jeffrey BirdDirectorBuy151,089$6.24$942,795.36View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/25/2012Jeffrey W BirdDirectorBuy575,356$3.49$2,007,992.44View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Horizon Pharma (NASDAQ:HZNP)
DateHeadline
07/29/16 07:30 AMHC Stocks Analysis: Horizon Pharma PLC (NASDAQ:HZNP), Pernix Therapeutics Holdings Inc (NASDAQ:PTX) - share market updates (press release)
07/29/16 07:30 AMAnalysts Ranking Activities: Exelixis, Inc. (NASDAQ:EXEL) , Horizon Pharma plc (NASDAQ:HZNP) - Street Updates
07/28/16 04:42 PMNew Broker Ratings For Horizon Pharma, Inc. (NASDAQ:HZNP ... - FTSE News
07/27/16 07:19 AMTwo Stocks to Watch: Horizon Pharma plc (NASDAQ:HZNP) , Hemispherx BioPharma, Inc. (NYSEMKT:HEB) - Street Updates
07/21/16 10:35 AMTake a look at Analyst Tips: Horizon Pharma plc (NASDAQ:HZNP) , Ionis Pharmaceuticals Inc (NASDAQ:IONS) - Street Updates
07/20/16 07:31 AMNotable Analysts Recommendation to Monitor: Humana Inc. (NYSE:HUM) , Horizon Pharma plc (NASDAQ:HZNP) - Street Updates
07/15/16 03:37 PMMarket Updates on Drugs - Generic Equities -- Mylan, Horizon Pharma, Allergan, and Diplomat Pharmacy
07/14/16 12:11 PMLigand Pharmaceuticals’s Performance Based on EV-to-EBITDA -
07/14/16 12:11 PMUnderstanding Ligand Pharmaceuticals’s PE Multiple -
07/14/16 08:03 AMInvestors Traded Stocks: Pfizer, Inc. (NYSE:PFE) , Horizon Pharma plc (NASDAQ:HZNP) - Street Updates
07/13/16 04:56 PMNuvo Pharmaceuticals : TM) Inc. Announces Pennsaid 2% Phase 3 Trial to Support Regulatory Approvals in the E.U., Canada and Australia
07/13/16 09:50 AMForeigners made record U.S. investments in 2015, but not for all best reasons -
07/13/16 07:27 AMShort Term Rating on Horizon Pharma plc (HZNP) - Trade Calls
07/13/16 07:27 AMMorgan Stanley Weighs In on Two Biotechs: Relypsa Inc (RLYP), Horizon Pharma PLC (HZNP) - Smarter Analyst
07/13/16 06:43 AMNuvo Pharmaceuticals™ Inc. Announces Pennsaid 2% Phase 3 Trial to Support Regulatory Approvals in the E.U., Canada and Australia - [at noodls] - MISSISSAUGA, ON, July 13, 2016/CNW/ - Nuvo Pharmaceuticals Inc. (TSX:NRI) (Nuvo or the Company) today announced it will conduct a new placebo-controlled, multi-centre Phase 3 trial (Trial) in Germanyto ...
07/12/16 04:49 PMHC Stocks Zone: Baxter International Inc (NYSE:BAX), Horizon Pharma PLC (NASDAQ:HZNP) - share market updates (press release)
07/12/16 10:06 AMCheck out Horizon’s Huge Upside Potential -
07/11/16 10:26 AMHorizon Pharma (HZNP) Stock Rises, Morgan Stanley Upgrades -
07/09/16 04:10 PMNoble Energy, Inc. (NYSE:NBL) & Horizon Pharma (NASDAQ:HZNP) are Hot Stocks - Money News (press release)
07/07/16 07:23 AMNew Drugs for Insys Therapeutics Inc (INSY) and Horizon Pharma PLC(HZNP) Lead Analysts' Bullish Outlook - Smarter Analyst
07/07/16 06:11 AMHorizon Pharma plc to Host Second-Quarter 2016 Conference Call and Webcast on August 8, 2016 - [at noodls] - DUBLIN, Ireland, July 07, 2016 (GLOBE NEWSWIRE) -- Horizon Pharma plc (Nasdaq:HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing ...
07/07/16 06:06 AMInside Horizon’s Orphan and Rheumatology Business Unit -
07/07/16 06:06 AMWhat’s Really Driving Horizon’s Valuation? -
07/04/16 04:06 PMBroker Outlook For The Week Ahead Horizon Pharma, Inc. (NASDAQ:HZNP) - Fiscal Standard
07/01/16 07:20 AMBroadfin Capital LLC Increased Horizon Pharma Plc (NASDAQ:HZNP) by $101.17 Million as Shares Declined - Engelwood Daily
07/01/16 07:20 AMHC Stocks Reports: Horizon Pharma PLC (NASDAQ:HZNP), Pernix Therapeutics Holdings Inc (NASDAQ:PTX) - share market updates (press release)
06/30/16 04:48 PM4 Reasons To Own Horizon Pharma Shares - Benzinga
06/30/16 04:48 PMAnalysts and Technical Insights on Horizon Pharma Plc (NASDAQ:HZNP) - Street Report
06/30/16 02:01 PMThe Truth behind Horizon’s EV-to-EBITDA Performance -
06/30/16 07:23 AMIs Horizon Pharma (NASDAQ:HZNP) a Sell? Get to Know What BMO Capital Thinks - Engelwood Daily
06/29/16 04:28 PMAnalyst Rating Update on Horizon Pharma plc (HZNP) - Trade Calls
06/29/16 04:11 PM4 Reasons To Own Horizon Pharma Shares - Horizon Pharma plc (NASDAQ: HZNP) shares traded nearly 7 percent higher Wednesday. Investors in the name have responded to a couple news items, a new Outperform rating from BMO analyst Gary Nachman and news of the company's sNDA submission for Ravicti. Nachman set a $29 price target on Horizon shares, a target which represented a near doubling of the price from the high $16 range the stock traded in during Wednesday's session. The BMO analyst highlighted four reasons to own Horizon Pharma. "[T]ransition to more of an orphan drug story is unfolding, including an attractive pipeline led by ...Full story available on Benzinga.com
06/29/16 04:09 PMInside Neurocrine Biosciences’ Analyst Recommendations in 2016 -
06/29/16 03:47 PMHorizon Pharma (HZNP) Stock Closed Up as BMO Initiates Coverage -
06/29/16 07:19 AMHorizon Pharma (HZNP) Announces Submission of RAVICTI sNDA o Expand Age Range for Management of Urea ... - StreetInsider.com
06/29/16 07:11 AMClinigen Group - New MA program with Horizon Pharma - [at noodls] - 29 June 2016 CLINIGEN GROUP PLC Clinigen and Horizon Pharma enter partnership to initiate European Managed Access program for RAVICTI® (glycerol phenylbutyrate) Oral Liquid Clinigen Group plc's (AIM: CLIN, ...
06/29/16 06:21 AMHorizon Pharma plc Submits Supplemental New Drug Application for RAVICTI(R) (glycerol phenylbutyrate) Oral Liquid to Expand Age Range for Management of Urea Cycle Disorders - [at noodls] - DUBLIN, IRELAND -- (Marketwired) -- 06/29/16 -- Horizon Pharma plc (NASDAQ: HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing ...
06/29/16 06:11 AMClinigen and Horizon Pharma enter partnership to initiate European Managed Access program for RAVICTI® (glycerol phenylbutyrate) Oral Liquid - [at noodls] - Clinigen Group plc's (AIM: CLIN, 'Clinigen' or the 'Group') Idis Managed Access (MA) division and Horizon Pharma plc (NASDAQ: HZNP), have initiated a Managed Access program in Europe for Horizon's RAVICTI® ...
06/28/16 04:28 PMHorizon Pharma plc Added to Russell 2000® and 3000® Indexes
06/28/16 04:28 PMExclusive: Horizon Pharma explores potential stake sale - sources
06/28/16 09:25 AMExclusive: Horizon Pharma explores potential stake sale - sources - Reuters
06/28/16 09:18 AMHere’s Why Traders Are Watching These Stocks Today -
06/28/16 07:58 AMHorizon Pharma Plc breached its 50 day moving average in a Bearish Manner : HZNP-US : June 28, 2016 -
06/27/16 04:30 PMHorizon Pharma Plc Ord Ireland (NASDAQ:HZNP) Sellers Covered 8.78% of Their Shorts - Engelwood Daily
06/27/16 03:31 PMHorizon Pharma plc Added to Russell 2000(R) and 3000(R) Indexes - [at noodls] - DUBLIN, IRELAND -- (Marketwired) -- 06/27/16 -- Horizon Pharma plc (NASDAQ: HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing ...
06/26/16 03:56 PMHow Many Horizon Pharma PLC (NASDAQ:HZNP)'s Analysts Are Bearish? - Engelwood Daily
06/24/16 07:09 AMHorizon Pharma plc (NASDAQ:HZNP) Earnings Glance and Target Price Review - Engelwood Daily
06/24/16 07:09 AMHorizon Pharma plc (NASDAQ:HZNP) Analyst Rating Update - Investor Newswire
06/24/16 07:09 AMBroadfin Capital LLC Increased Horizon Pharma Plc (NASDAQ:HZNP) by $101.17 Million as Shares Declined - Press Telegraph
06/24/16 07:09 AMHC Stocks Analysis: Horizon Pharma PLC (NASDAQ:HZNP), Prima BioMed Ltd (ADR) (NASDAQ:PBMD) - share market updates (press release)

Social

About Horizon Pharma

Horizon Pharma logoHorizon Pharma plc, formerly Vidara Therapeutics International Public Limited Company, is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring or in-licensing and commercializing differentiated products. It markets approximately nine medicines through its orphan, primary care and rheumatology business units. Its segment focuses on the identification, development, acquisition and commercialization of differentiated and accessible medicines. Its marketed medicines include ACTIMMUNE (interferon gamma-1b), BUPHENYL (sodium phenylbutyrate) Tablets and Powder, DUEXIS (ibuprofen/famotidine), KRYSTEXXA (pegloticase), MIGERGOT (ergotamine tartrate and caffeine suppositories), PENNSAID (diclofenac sodium topical solution) 2% w/w, or PENNSAID 2%, RAVICTI (glycerol phenylbutyrate) Oral Liquid, RAYOS (prednisone) delayed-release tablets and VIMOVO (naproxen/esomeprazole magnesium). It also developed DUEXIS and RAYOS, known as LODOTRA.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: Pharmaceuticals
  • Exchange: NASDAQ
  • Symbol: HZNP
  • CUSIP: 44047T10
Key Metrics:
  • Previous Close: $19.85
  • 50 Day Moving Average: $17.86
  • 200 Day Moving Average: $16.94
  • P/E Ratio: 254.81
  • P/E Growth: 0.61
  • Market Cap: $3.15B
  • Beta: 1.88
  • Current Year EPS Consensus Estimate: $2.37 EPS
  • Next Year EPS Consensus Estimate: $2.73 EPS
Additional Links:
Horizon Pharma (NASDAQ:HZNP) Chart for Friday, July, 29, 2016